Roflumilast tablets (Roflumilast)-DALIRESP medication instructions and dosage

Roflumilast - DALIRESP is a drug used to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD), especially those with chronic bronchitis and a history of exacerbations. When using this drug, it is important to follow the correct regimen and dosage to ensure efficacy and reduce the occurrence of side effects.

The initial dosage regimen of Roflumilast tablets is to take 250 micrograms (mcg) once daily for 4 weeks. This dose is mainly used to help patients adapt to the drug and observe its tolerance. It is important to note that 250 mcg is not an effective therapeutic dose, so dose adjustments should be made after 4 weeks.

After 4 weeks of initial treatment, patients are required to increase the dose to 500 micrograms (mcg) once daily. This maintenance dose is a clinically proven effective dose that can significantly reduce the risk of exacerbations in patients with COPD. Roflumilast tablets can be taken before or after meals, and patients can choose the appropriate time to take them according to their personal lifestyle habits. However, to ensure optimal absorption of the drug, it is recommended to take it at the same time every day to keep blood concentrations stable.

During the use of roflumilast tablets, patients should pay close attention to their physical reactions. If obvious discomfort or side effects occur, they should communicate with their doctor in a timely manner. Studies have shown that some patients may experience gastrointestinal discomfort, insomnia, headache and other adverse reactions while using roflumilast. Therefore, doctors need to fully inform patients of possible side effects when prescribing and conduct corresponding monitoring.

It is worth reminding that roflumilast tablets are not a bronchodilator and are not suitable for relieving acute bronchospasm. Therefore, patients with acute exacerbations of COPD still need to be treated with traditional bronchodilators.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf##